文献速递妇科

绝经激素治疗对韩国绝经后女性心血管风险的影响:一项全国性队列研究

Effect of menopausal hormonal therapy on cardiovascular risks in Korean postmenopausal women: A nationwide cohort study.
PubMed 文献 · BJOG · 2024-03-11

该全国性队列研究纳入2002至2019年韩国国家健康保险数据库中年龄≥40岁、无心血管病史的绝经后女性1 120 705例,按是否接受绝经激素治疗(MHT)分为MHT组319 007例和非MHT组801 698例。结果显示,与非MHT组相比,替勃龙、口服雌激素或经皮雌激素使用者的心血管疾病风险升高,风险主要源于卒中风险增加。

要点

  • 与非MHT组相比,替勃龙(HR 1.143)、口服雌激素(HR 1.246)和经皮雌激素(HR 1.289)使用者的心血管疾病风险升高。
  • 心血管疾病风险升高主要归因于卒中风险增加。
  • 无论MHT起始年龄或医生专科如何,风险趋势一致。

核心结论

  • 该全国性队列研究显示,与非MHT使用者相比,替勃龙及口服或经皮雌激素使用者的心血管疾病风险升高,且主要由卒中风险增加驱动。

研究设计与样本

  • 基于韩国国家健康保险服务数据库的全国性人群队列研究,纳入2002至2019年间年龄≥40岁进入绝经且无心血管疾病史的女性1 120 705例,按MHT状态分为MHT组(n=319 007)和非MHT组(n=801 698)。

主要发现

  • 心血管疾病(心肌梗死和卒中的复合终点)发生率在非MHT组为59 266例(7.4%),在MHT组为17 674例(5.5%)。
  • 调整混杂因素后,与非MHT组相比,替勃龙使用者心血管疾病风险升高(HR 1.143,95%CI 1.117-1.170)。
  • 调整混杂因素后,与非MHT组相比,口服雌激素使用者心血管疾病风险升高(HR 1.246,95%CI 1.198-1.295)。
  • 调整混杂因素后,与非MHT组相比,经皮雌激素使用者心血管疾病风险升高(HR 1.289,95%CI 1.066-1.558)。
  • 无论MHT起始年龄或医生专科如何,风险趋势一致;在替勃龙使用者中,进入绝经至开始服用替勃龙的时间较长及使用任何剂量(1.25或2.5 mg)均与非MHT使用者相比心血管疾病风险较高相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the association between menopausal hormonal therapy (MHT) and the risk of cardiovascular disease (CVD), according to various regimens, dosages, routes of administration and starting ages of MHT. DESIGN: A population-based cohort study using the Korean National Health Insurance Services database. SETTING: Nationwide health insurance database. POPULATION: Women who reported entering menopause at an age of ≥40 years with no history of CVD in the national health examination. METHODS: The study population comprised 1 120 705 subjects enrolled between 2002 and 2019, categorised according to MHT status (MHT group, n = 319 007; non-MHT group, n = 801 698). MAIN OUTCOME MEASURES: Incidence of CVD (a composite of myocardial infarction and stroke). RESULTS: The incidence of CVD was 59 266 (7.4%) in the non-MHT group and 17 674 (5.5%) in the MHT group. After adjusting for confounding factors, an increased risk of CVD was observed with the administration of tibolone (hazard ratio, HR 1.143, 95% CI 1.117-1.170), oral estrogen (HR 1.246, 95% CI 1.198-1.295) or transdermal estrogen (HR 1.289, 95% CI 1.066-1.558), compared with the non-MHT group; the risk was based on an increased risk of stroke. The risk trends were consistent regardless of the age of starting MHT or the physicians' specialty. Among tibolone users, a longer period from entering menopause to taking tibolone and the use of any dosage (1.25 or 2.5 mg) were linked with a higher risk of CVD, compared with non-MHT users. CONCLUSIONS: This nationwide cohort study demonstrated an increased risk of CVD, driven mainly by an increased risk of stroke, among tibolone and oral or transdermal estrogen users, compared with that of non-MHT users.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Yuk JS, Kim GS, Byun YS, et al. Effect of menopausal hormonal therapy on cardiovascular risks in Korean postmenopausal women: A nationwide cohort study. BJOG. 2024. PMID: 38465460. doi:10.1111/1471-0528.17803

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。